What is the “FDA approves AstraZeneca's Camizestrant?” market asking?

It asks whether the following will happen: FDA approves AstraZeneca's Camizestrant? Traders buy Yes shares if they think it will and No shares if they think it will not.

What do the Yes and No prices mean?

At the last observation Yes traded at 0.0¢ and No at 100.0¢. A Yes share pays $1 if the market resolves Yes, so its price is the market's implied probability: 0.0% for Yes and 100.0% for No. The two prices add up to about one dollar.

How did this market resolve?

It resolved No on 16 May 2026. Trading has stopped; the record of prices, holders and trades stays on this page.

How does this market resolve?

As of market creation, the FDA's expected decision date for the specified application is April 30, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for AstraZeneca's Camizestrant as a treatment for HR+/HER2- advanced or metastatic breast cancer with ESR1 mutation by May 14, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking…

What is the difference between volume, liquidity and open interest?

Volume is the dollar value of shares traded in a period, liquidity is the dollar value resting in the order book ready to be traded against, and open interest is the value of all shares currently held. Volume measures activity, liquidity measures how easily you can trade, and open interest measures how much is at stake.

Who still holds shares in this market?

13 public wallets still held shares when Vultax last looked. Winners usually redeem their shares after settlement, so the remaining holders are mostly on the losing side.

Where does this data come from and how fresh is it?

Prices, the order book, holders and the trade tape come from Polymarket's public order book and data API. Vultax records each observation with its own timestamp (market facts last updated May 16, 7:12 AM UTC) and shows a value as unavailable rather than as zero when a source has not answered.

Can I trade this market on Vultax?

No. Vultax is a research and paper-trading terminal; it does not execute orders. The trade controls open the official market on Polymarket (https://polymarket.com/event/fda-approves-astrazenecas-camizestrant) or the Vultax predictions monitor, where you can track the market and paper trade it.

Resolved No: FDA approves AstraZeneca's Camizestrant?

Market referencefda-approves-astrazenecas-camizestrantUpdated May 16, 2026 UTC

Resolved

No · settled May 16, 2026 UTC

Yes

0.0%

100.0%

Final Yes 0¢Final No 100¢

Lifetime volume

$2.8K

Resolved

Settled

May 16, 2026 UTC

Source Evidence

Evidence coverage

Items

Fetched

Latest

Aug 13, 2026 UTC

Public Polymarket market/event context is available; Vultax source-pack coverage is tracked separately.

Depth

Observed

May 16, 2026 UTC

This closed market has no live orderbook depth; the public close quote is shown for context.

Trading stateMarket usability at the displayed observation.

Market state

Resolved

Order book

Captured book available

Final outcome

The resolved venue state is treated as proof of resolution; holder and trade rows are settlement context.

Holder depthCapped public top-holder sample.

Rows loaded

Wallets

Top 10 share

98%

Yes / No shares

483.55 / 4.1

Rows reflect the positive holders returned for this market, not venue-wide open interest.

Recent tapeLatest public market trades.

Trades loaded

112

Wallets

Loaded notional

PricesPolymarket CLOB price history · daily closes · latest observation May 16, 12:00 AM UTC

Depth historyCheckSubscriber depth access is checked only when requested, keeping the public page fast.

Bucket	Close	Mid
May 16, 12:00 AM UTC	3.1%	3.1%
May 15, 12:00 AM UTC	3.1%	3.1%
May 14, 12:00 AM UTC	7.5%	7.5%

Questions

Questions about this market

What is the “FDA approves AstraZeneca's Camizestrant?” market asking?: It asks whether the following will happen: FDA approves AstraZeneca's Camizestrant? Traders buy Yes shares if they think it will and No shares if they think it will not.
What do the Yes and No prices mean?: At the last observation Yes traded at 0.0¢ and No at 100.0¢. A Yes share pays $1 if the market resolves Yes, so its price is the market's implied probability: 0.0% for Yes and 100.0% for No. The two prices add up to about one dollar.
How did this market resolve?: It resolved No on 16 May 2026. Trading has stopped; the record of prices, holders and trades stays on this page.
How does this market resolve?: As of market creation, the FDA's expected decision date for the specified application is April 30, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for AstraZeneca's Camizestrant as a treatment for HR+/HER2- advanced or metastatic breast cancer with ESR1 mutation by May 14, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking…
What is the difference between volume, liquidity and open interest?: Volume is the dollar value of shares traded in a period, liquidity is the dollar value resting in the order book ready to be traded against, and open interest is the value of all shares currently held. Volume measures activity, liquidity measures how easily you can trade, and open interest measures how much is at stake.

Analytics

Bucket

Mid

Spread

Volume

Trades

May 16, 12:00 AM UTC

3.1%

May 15, 12:00 AM UTC

3.1%

May 14, 12:00 AM UTC

7.5%